A Phase 1 interventional study of Clopidogrel and Dabigatran high dose in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-06-24.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of the study (Main Part 2) was to investigate whether and to which extent a combination of multiple oral doses (steady state conditions) of 75 mg of clopidogrel q.d. (after a loading dose of 300 mg) and multiple doses of 150 mg of dabigatran etexilate b.i.d. at steady state affects pharmacokinetic and pharmacodynamic parameters of dabigatran etexilate and clopidogrel.
The objective of the preceding Pilot Part 1 of the study was to explore the effect of a single dose of 300 mg clopidogrel administered after multiple doses of 75 mg and 150 mg dabigatran had reached steady state, regarding safety as well as pharmacokinetic and pharmacodynamic parameters.
The Main Part 3 of the study moreover was to compare intra-individually the effects of a single dose of 600 mg clopidogrel with the same dose, 600 mg clopidogrel, given additionally to multiple doses of 150 mg dabigatran in steady state condition with respect to safety and pharmacokinetic and pharmacodynamic parameters.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects who in the investigator's judgement are perceived as having an increased risk of bleeding, for example because of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
multiple-dose, fixed-sequence with 2 periods of 4 days separated by a washout period of at least 14 days. A single dose of 300 mg clopidogrel will be given on top of 75 mg or 150 mg dabigatran in steady state.
Drug: Clopidogrel · Drug: Dabigatran high dose · Drug: Dabigatran low dose
clopidogrel + dabigatran / clopidogrel / dabigatran in randomized order
Drug: Clopidogrel · Drug: Dabigatran high dose · Drug: Dabigatran low dose
intra-individual comparison with the fixed sequence of a single dose of 600mg clopidogrel alone and the combination of dabigatran 150 mg in steady state plus single dose of 600 mg clopidogrel
Drug: Clopidogrel · Drug: Dabigatran high dose
AUCτ,ss (area under the concentration-time curve of the analyte in plasma over one dosing interval at steady state)
for total dabigatran, clopidogrel and the inactive metabolite SR26334
Time frame: up to 19 days
AUC0-24,1 (area under the concentration-time curve of the analyte in plasma over one dosing interval after the loading dose)
for clopidogrel and the inactive metabolite SR26334
Time frame: up to 19 days
Cmax,ss (maximum measured concentration of the analyte in plasma at steady state)
for total dabigatran, clopidogrel and the inactive metabolite SR26334
Time frame: up to 19 days
Cmax,1 (maximum measured concentration of the analyte in plasma after the loading dose)
for total dabigatran, clopidogrel and the inactive metabolite SR26334
Time frame: up to 19 days
AUECIPA,0-24 (area under the effect curve of inhibition of platelet aggregation after the first dose of clopidogrel)
Time frame: up to 19 days
Emax,IPA,0-24 (maximum percentage change - compared to baseline - in adenosine diphosphate-induced platelet aggregation after the loading dose of clopidogrel)
Time frame: baseline, up to 19 days
tmax (time from dosing to the maximum concentration of the analyte in plasma)
Clopidogrel and SR 26334 after the loading dose
Time frame: up to 8 weeks
AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)
Clopidogrel and SR 26334 after the loading dose
Time frame: up to 8 weeks
AUC0-tz (area under the concentration-time curve of the analyte in plasma from the time point 0 to the last quantifiable analyte plasma concentration)
Clopidogrel and SR 26334 after the loading dose
Time frame: up to 8 weeks
λz (terminal rate constant in plasma)
Clopidogrel and SR 26334 after the loading dose
Time frame: up to 8 weeks
t1/2 (terminal half-life of the analyte in plasma)
Clopidogrel and SR 26334 after the loading dose
Time frame: up to 8 weeks
MRTpo (mean residence time of the analyte in the body after oral administration)
Clopidogrel and SR 26334 after the loading dose
Time frame: up to 8 weeks
CL/F (apparent clearance of the analyte in the plasma after extravascular administration)
Clopidogrel and SR 26334 after the loading dose
Time frame: up to 8 weeks
Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)
Clopidogrel and SR 26334 after the loading dose
Time frame: up to 8 weeks
Cmax, ss
free dabigatran after multiple dosing
Time frame: up to 8 weeks
AUCτ,ss
free dabigatran after multiple dosing
Time frame: up to 8 weeks
AUC0-tz,ss (area under the concentration-time curve of the analyte in plasma from the time point 0 after the last dose at steady state to the last quantifiable analyte plasma concentration within the uniform dosing interval τ)
Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing
Time frame: up to 8 weeks
tz,ss (time of last measureable concentration of the analyte in plasma within the dosing interval τ at steady state)
Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing
Time frame: up to 8 weeks
tmax,ss (time from last dosing to the maximum concentration of the analyte in plasma at steady state on day 4)
Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing
Time frame: up to 8 weeks
CL/F,ss (apparent clearance of the analyte in the plasma at steady state after extravascular multiple dose administration)
Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing
Time frame: up to 8 weeks
Cmin,ss (minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ)
Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing
Time frame: up to 8 weeks
tmin,ss (time from last dosing to the minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ)
Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing
Time frame: up to 8 weeks
Cpre,ss (predose concentration of the analyte in plasma at steady state immediately before administration of the next dose)
Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing
Time frame: up to 8 weeks
MRTpo,ss (mean residence time of the analyte in the body at steady state after oral administration)
Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing
Time frame: up to 8 weeks
Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following an extravascular administration)
Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing
Time frame: up to 8 weeks
PTF (peak trough fluctuation)
Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing
Time frame: up to 8 weeks
Cavg (average concentration of the analyte in plasma at steady state over a uniform dosing interval)
Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing
Time frame: up to 8 weeks
AUECt1-t2 (area under the effect curve (baseline corrected by ratio))
for activated partial thromboplastin time, thrombin time and ecarin clotting time
Time frame: up to 8 weeks
ERmax (maximum effect ratio)
for activated partial thromboplastin time, thrombin time and ecarin clotting time
Time frame: up to 8 weeks
tmax (time to maximum effect)
for activated partial thromboplastin time, thrombin time and ecarin clotting time
Time frame: up to 8 weeks
Occurence of Adverse Events
Time frame: up to 13 weeks
Assessment of Tolerability by investigator
Time frame: up to 13 weeks
No study locations are listed for this record.
The record gives a start of Feb 2009 and a primary completion of Jul 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clopidogrel